A half-life extended monoclonal antibody targeting kallikreins 5 and 7, in Phase 2 proof-of-concept trial for atopic dermatitis.
TRIV-509 is a half-life extended monoclonal antibody that selectively targets kallikreins 5 and 7 (KLK5/7), key enzymes implicated in skin barrier dysfunction, inflammation, and itch. Preclinical data demonstrated superior efficacy compared to IL-4R inhibition in atopic dermatitis models, and human explant studies showed improved barrier integrity, reduced epidermal thickness, and elevated levels of a key protein needed for skin barrier function.
The first patient has been dosed in a global Phase 2 proof-of-concept trial for moderate-to-severe atopic dermatitis. TRIV-509 is positioned for quarterly subcutaneous dosing and is designed to address the root cause of the disease rather than merely modulating inflammatory pathways.
AbCellera Biologics
Abcl575
abcellera.com
Sanofi
Dupixent
sanofi.com
Eli Lilly and Company
Ebglyss
lilly.com
| Attribute | Triv-509 | Abcl575 | Dupixent | Ebglyss | |
|---|---|---|---|---|---|
| Provider |  | | | | |
| Founded | 2023 | 2012 | 1973 | 1876 | |
| Sells To | B2B, Enterprise | Enterprise, Government | Enterprise | Consumers, Enterprise | |
| Pricing Model | Licensing, Pre-Revenue | Recurring, Software | Recurring | Recurring, Software, Transactional | |
| Ownership | Private, Venture-backed | Public | Public | Public |
Provider
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed
Provider
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 1973
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
Prescription dermatology medicines for moderate-to-severe skin conditions.
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
Prescription dermatology medicines for moderate-to-severe skin conditions.
